GlassScriptPhysician profile
Kayla Newstrom
NPI 1275230732
$490.43
in general payments reported to CMS, 2019-2025
11 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $23.85 · 2024: $85.45 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $103.81 | 2024-2025 | Farxiga |
| Novo Nordisk INC | $101.22 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $60.88 | 2025 | Mounjaro, Zepbound |
| Globus Medical, INC. | $49.57 | 2025 | Senza |
| Antares Pharma, INC. | $35.93 | 2024-2025 | Xyosted |
| Esperion Therapeutics, INC. | $33.90 | 2025 | Nexletol |
| Exact Sciences Corporation | $31.38 | 2025 | Cologuard Collection Kit |
| Organon LLC | $23.85 | 2023 | Nexplanon |
| Teva Pharmaceuticals USA, INC. | $18.41 | 2025 | Austedo Xr |
| Amgen INC. | $17.30 | 2024 | Repatha |
| Currax Pharmaceuticals LLC | $14.18 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Newstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.